Dr George Sharbeen is deputy lead of the Pancreatic Cancer Translational Research Group (UNSW Sydney) and a senior research fellow in the Poor Outcomes Cancers focus area, within the Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group. His research is focused on developing more effective therapies for pancreatic cancer and his most notable achievements include co-development of a novel nanomedicine for pancreatic cancer and a 3D human pancreatic cancer explant model, and the identification of an amino acid transporter as a stromal remodelling target in pancreatic cancer (Sharbeen et al, Cancer Research, 2021). His work formed the foundation for the SPEAR (Sulfasalazine in patients with PancrEatic AdenocaRcinoma) clinical trial (part of the Molecular Screening and Therapeutics [MoST] pancreas cancer program) where Dr Sharbeen co-leads the correlative science studies. His research success has been recognised by a number of awards and competitive research funding including Cancer-Institute NSW Early-Career and Mid-Career Fellowships. He is currently funded by Pankind Accelerator and NSW Health Advanced Therapeutics Impact grants.